Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 19, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
2,256
Not yet recruiting, industry sponsors
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting7,024
- Not yet recruiting2,256
- Completed64,782
2,256 trials
Showing 1 to 25, recently updated first.
- A Study of HLX105 in Patients With Advanced or Metastatic Solid TumorsNot yet recruiting
Shanghai Henlius BiotechIndustry
NCT07949669 · 42 participants (planned) · Start Nov 30, 2026 · Primary completion Nov 30, 2027
Drug: HLX105 · For: Solid Tumor (Phase I)
- Phase 2 Study to Evaluate Dose Optimization and Anti-tumor Activity of Atebimetinib in Participants With Advanced or Metastatic NSCLC.Not yet recruiting
Immuneering CorporationIndustry
NCT07946848 · 100 participants (planned) · Start Dec 2026 · Primary completion May 2029
Drug: Atebimetinib; Cemiplimab and 2 more · For: NSCLC (Advanced Non-small Cell Lung Cancer); Non-Squamous Non Small Cell Lung Cancer; Metastatic Non-Small Lung Cell Cancer and 2 more
Sites: Fairfax, Virginia
- A Phase II Clinical Study Evaluating the Efficacy and Safety of SXRN Injection in Patients With Cancer CachexiaNot yet recruiting
Jiangsu Guiqiong Pharmaceutical Co., Ltd.Industry
NCT07890324 · 96 participants (planned) · Start Dec 2026 · Primary completion Aug 2027
Drug: SXRN Injection; SXRN Injection and 1 more · For: Cachexia-Anorexia Syndrome; Cachexia; Cancer
Sites: Beijing, China
- Study of Twice Yearly Lenacapavir, Teropavimab, and Zinlirvimab in the Pediatric Population With HIV-1Pivotal-lookingNot yet recruiting
Gilead SciencesGilead Sciences (GILD)
NCT07947732 · 25 participants (planned) · Start Nov 2026 · Primary completion Nov 2028
Drug: Lenacapavir Tablet; Lenacapavir Injection and 2 more · For: HIV-1-infection
Sites: The Bronx, New York; Salt Lake City, Utah
- A STUDY OF SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF FXS6837 CAPSULES IN PARTICIPANTS WITH HEPATIC IMPAIRMENT AND NORMAL HEPATIC FUNCTIONNot yet recruiting
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Industry
NCT07949799 · 24 participants (planned) · Start Dec 17, 2026 · Primary completion Apr 29, 2027
Drug: FXS6837 capsule · For: Hepatic Impairment
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyDaiichi Sankyo (DSNKY)
NCT07949344 · 40 participants (planned) · Start Dec 1, 2026 · Primary completion Jun 30, 2030
Drug: Quizartinib; Chemotherapy · For: Acute Myeloid Leukemia
- A Phase I Clinical Study of Oral ZL-65 Tablets in Healthy and Obese Participants With Cardiovascular RiskPivotal-lookingNot yet recruiting
Chengdu Zenitar Biomedical Technology Co., LtdIndustry
NCT07946783 · 103 participants (planned) · Start Nov 19, 2026 · Primary completion Sep 30, 2027
Drug: Single-ascending Dose (SAD) study and Food Effect (FE) study; Multiple-ascending Doses (MAD) study and 1 more · For: Obesity With Cardiovascular Risk Study
Sites: Melbourne, Australia
- Study to Evaluate the Effect of Crinecerfont on Androgen Reduction and Related Outcomes in Adults With Classic Congenital Adrenal Hyperplasia (CAH)Pivotal-lookingNot yet recruiting
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT07947368 · 100 participants (planned) · Start Nov 2026 · Primary completion Jan 2028
Drug: Crinecerfont · For: Congenital Adrenal Hyperplasia
- Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Subcutaneous Injections of Elamipretide in Pediatric Subjects With Barth SyndromeNot yet recruiting
Stealth BioTherapeutics Inc.Industry
NCT07927972 · 6 participants (planned) · Start Nov 2026 · Primary completion May 2027
Drug: Elamipretide · For: Barth Syndrome
Sites: Birmingham, Alabama; Palo Alto, California; Peoria, Illinois · 7 sites in all
- A Study of Combogesic® 325 in Adolescent Patients With Moderate to Severe Postoperative Pain Associated With Orthopedic SurgeryPivotal-lookingNot yet recruiting
AFT Pharmaceuticals, Ltd.Industry
NCT07225140 · 180 participants (planned) · Start Jan 2027 · Primary completion Oct 2027
Drug: Combogesic® tablets; Acetaminophen 500mg and 1 more · For: Post Operative Pain, Acute
Sites: Orlando, Florida
- A Long-Term Follow-Up Study of Subjects With Stargardt Disease (STGD1) Treated With SB-007Not yet recruiting
Splice BioIndustry
NCT07948005 · 55 participants (planned) · Start Dec 1, 2026 · Primary completion Dec 31, 2035
Drug: No new intervention · For: Stargardt Disease; Stargardt Macular Degeneration; Stargardt Macular Dystrophy
- Assessing Prognostic Value of Markers of Cardiac Disease Progression in ATTR-CM Patients Treated With TafamidisNot yet recruiting
PfizerPfizer (PFE)
NCT07947940 · 1 participants (planned) · Start Nov 24, 2026 · Primary completion Mar 31, 2027
Drug: Tafamidis · For: ATTR-CM (Transthyretin Amyloid Cardiomyopathy)
- Safety and Drug Concentrations of REGN20566 in Adults With Overweight or ObesityPivotal-lookingNot yet recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07947966 · 304 participants (planned) · Start Dec 14, 2026 · Primary completion Feb 2, 2028
Drug: REGN20566; Placebo · For: Overweight; Obesity
- A Phase III Study of WSD0922-FU Versus Chemotherapy In Patients With C797S+ Advanced Non-small Cell Lung CancerPivotal-lookingNot yet recruiting
Wayshine Biopharm, Inc.Industry
NCT07948408 · 196 participants (planned) · Start Dec 10, 2026 · Primary completion May 1, 2028
Drug: WSD0922-FU; Platinum-based doublet chemotherapy (Pemetrexed and Cisplatin or Carboplatin) · For: Non Small Cell Lung Cancer (NSCLC)
Sites: Shanghai, China
- A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NEO 1306 in Healthy ParticipantsNot yet recruiting
NeolaiaBioIndustry
NCT07948447 · 80 participants (planned) · Start Dec 2026 · Primary completion May 2027
Drug: NEO-1306; NEO-1306 and 10 more · For: IBD (Inflammatory Bowel Disease); Healthy Adult Participants
Sites: Adelaide, Australia
- YSCH-01 for Recurrent or Progressive GlioblastomaNot yet recruiting
Shanghai Yuansong Biotechnology Co., Ltd.Industry
NCT07948109 · 32 participants (planned) · Start Nov 10, 2026 · Primary completion Dec 2028
Drug: YSCH-01 · For: Recurrent Glioblastoma (WHO-Grade IV Glioma); Progressive Glioblastoma; Recurrent Glioblastoma
Sites: Shanghai, China
- A Study of GSK5864399 Administered Alone or in Combination With Other Anti-cancer Agents in Participants With Solid TumoursPivotal-lookingNot yet recruiting
GlaxoSmithKlineGSK (GSK)
NCT07947134 · 155 participants (planned) · Start Nov 25, 2026 · Primary completion Nov 16, 2029
Drug: GSK5864399 · For: Solid Tumours
- Ph 1/2 Study to Evaluate Safety & Tolerability of FMC-242 Alone and in Combination in Adults With Advanced Solid TumorsNot yet recruiting
Frontier Medicines CorporationIndustry
NCT07944092 · 282 participants (planned) · Start Dec 2026 · Primary completion Jan 2029
Drug: FMC-242; Trastuzumab (or biosimilar) and 3 more · For: Locally Advanced Solid Tumor
- A Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of UBT48128 Tablets in Healthy ParticipantsNot yet recruiting
The United Bio-Technology (Hengqin) Co., Ltd.Industry
NCT07922798 · 60 participants (planned) · Start Dec 1, 2026 · Primary completion Dec 29, 2026
Drug: UBT48128; Placebo · For: Overweight , Obesity
Sites: Changsha, China
- A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid TumorsNot yet recruiting
PfizerPfizer (PFE)
NCT07897721 · 268 participants (planned) · Start Nov 9, 2026 · Primary completion Mar 22, 2030
Drug: PF-08165784; Fulvestrant and 3 more · For: Advanced Breast Cancer; Advanced or Metastatic Breast Cancer; Metastatic Breast Cancer (HR+/ HER2-) and 1 more
Sites: Fayetteville, Arkansas; Rogers, Arkansas; Springdale, Arkansas · 5 sites in all
NCT07934472 · 25 participants (planned) · Start Nov 15, 2026 · Primary completion Dec 31, 2028
Drug: Dapirolizumab pegol (DZP) · For: Systemic Lupus Erythematosus
- First-in-human Study of SAR448632 in Healthy Adult ParticipantsNot yet recruiting
SanofiSanofi (SNY)
NCT07944885 · 40 participants (planned) · Start Dec 1, 2026 · Primary completion Aug 15, 2027
Drug: Placebo; SAR448632 · For: Healthy Volunteer
- A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX49 in Advanced/Metastatic Solid TumorsPivotal-lookingNot yet recruiting
Shanghai Henlius BiotechIndustry
NCT07944690 · 222 participants (planned) · Start Nov 2026 · Primary completion Dec 2029
Drug: HLX49; Trastuzumab Deruxtecan for Injection (T-DXd) · For: Advanced/Metastatic Solid Tumors
Sites: Sunshine Coast, Australia; Beijing, China
- A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Treatment With H1 AntihistaminesPivotal-lookingNot yet recruiting
Longbio PharmaIndustry
NCT07946913 · 514 participants (planned) · Start Dec 7, 2026 · Primary completion Mar 24, 2028
Drug: LP-003 Injection; Omalizumab · For: Chronic Spontaneous Urticaria (CSU)
Sites: Beijing, China; Shenyang, China
- A Study of Risvutatug Rezetecan in Combination With Atezolizumab in Participants With Extensive Stage Small Cell Lung Cancer (EMBOLD-SCLC-303)Pivotal-lookingNot yet recruiting
GlaxoSmithKlineGSK (GSK)
NCT07947121 · 700 participants (planned) · Start Dec 25, 2026 · Primary completion Feb 24, 2031
Drug: Ris-Rez; Atezolizumab and 3 more · For: Lung Neoplasm
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.